Cover Image

Functional therapeutic target validation using pediatric zebrafish xenograft models

The survival rate among children with relapsed tumors remains poor, due to tumor heterogeneity, lack of directly actionable tumor drivers and multidrug resistance. Novel personalized medicine approaches tailored to each tumor are urgently needed to improve cancer treatment. Current pediatric precisi...

Full description

Saved in:
Bibliographic Details
Main Authors: Gatzweiler, Charlotte (Author) , Ridinger, Johannes (Author) , Herter, Sonja (Author) , Gerloff, Xenia F. (Author) , ElHarouni, Dina (Author) , Berker, Yannick (Author) , Imle, Roland (Author) , Schmitt, Lukas (Author) , Kreth, Sina (Author) , Stainczyk, Sabine (Author) , Ayhan, Simay (Author) , Najafi, Sara (Author) , Krunic, Damir (Author) , Frese, Karen S. (Author) , Meder, Benjamin (Author) , Reuss, David (Author) , Fiesel, Petra (Author) , Schramm, Kathrin (Author) , Blattner-Johnson, Mirjam (Author) , Jones, David T. W. (Author) , Banito, Ana (Author) , Westermann, Frank (Author) , Oppermann, Sina (Author) , Milde, Till (Author) , Peterziel, Heike (Author) , Witt, Olaf (Author) , Oehme, Ina (Author)
Format: Article (Journal)
Language:English
Published: 8 February 2022
In: Cancers
Year: 2022, Volume: 14, Issue: 3, Pages: 1-24
ISSN:2072-6694
DOI:10.3390/cancers14030849
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/cancers14030849
Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/2072-6694/14/3/849
Get full text
Author Notes:Charlotte Gatzweiler, Johannes Ridinger, Sonja Herter, Xenia F. Gerloff, Dina ElHarouni, Yannick Berker, Roland Imle, Lukas Schmitt, Sina Kreth, Sabine Stainczyk, Simay Ayhan, Sara Najafi, Damir Krunic, Karen Frese, Benjamin Meder, David Reuss, Petra Fiesel, Kathrin Schramm, Mirjam Blattner-Johnson, David T.W. Jones, Ana Banito, Frank Westermann, Sina Oppermann, Till Milde, Heike Peterziel, Olaf Witt and Ina Oehme
Description
Summary:The survival rate among children with relapsed tumors remains poor, due to tumor heterogeneity, lack of directly actionable tumor drivers and multidrug resistance. Novel personalized medicine approaches tailored to each tumor are urgently needed to improve cancer treatment. Current pediatric precision oncology platforms, such as the INFORM (INdividualized Therapy FOr Relapsed Malignancies in Childhood) study, reveal that molecular profiling of tumor tissue identifies targets associated with clinical benefit in a subgroup of patients only and should be complemented with functional drug testing. In such an approach, patient-derived tumor cells are exposed to a library of approved oncological drugs in a physiological setting, e.g., in the form of animal avatars injected with patient tumor cells. We used molecularly fully characterized tumor samples from the INFORM study to compare drug screen results of individual patient-derived cell models in functional assays: (i) patient-derived spheroid cultures within a few days after tumor dissociation; (ii) tumor cells reisolated from the corresponding mouse PDX; (iii) corresponding long-term organoid-like cultures and (iv) drug evaluation with the corresponding zebrafish PDX (zPDX) model. Each model had its advantage and complemented the others for drug hit and drug combination selection. Our results provide evidence that in vivo zPDX drug screening is a promising add-on to current functional drug screening in precision medicine platforms.
Item Description:Gesehen am 29.03.2022
Physical Description:Online Resource
ISSN:2072-6694
DOI:10.3390/cancers14030849

Similar Items